心脏恶病质与心力衰竭患者不良结局的关联:队列研究的荟萃分析
该荟萃分析检索PubMed、Web of Science和Embase至2025年2月7日,纳入9项队列研究共3821例心力衰竭患者,评估心脏恶病质对全因死亡和主要不良心血管事件(MACEs)的预后价值。固定效应模型显示,心脏恶病质与全因死亡风险(HR 1.59;95%CI 1.34-1.89)和MACEs风险(HR 2.41;95%CI 1.50-3.85)升高相关,且不同定义下患病率为11.2%-37.8%。
要点
- 心脏恶病质与心衰患者全因死亡风险升高59%相关(HR 1.59)。
- 不同定义下心脏恶病质患病率为11.2%-37.8%。
核心结论
- 心脏恶病质与心力衰竭患者全因死亡和MACEs风险升高独立相关。
- 评估心脏恶病质可为心衰患者提供有价值的预后信息。
研究设计与样本
- 本研究为荟萃分析,检索PubMed、Web of Science和Embase数据库至2025年2月7日。
- 纳入9项队列研究,共3821例心力衰竭患者,采用固定效应模型合并调整后HR及95%CI。
主要发现
- 心脏恶病质与全因死亡风险升高相关(HR 1.59;95%CI 1.34-1.89)。
- 心脏恶病质与MACEs风险升高相关(HR 2.41;95%CI 1.50-3.85)。
- 不同定义下心脏恶病质患病率为11.2%-37.8%。
- 亚组分析显示,无论研究设计、心衰亚型、样本量、国家、年龄、恶病质定义、随访时长、基线BMI、LVEF及是否调整肾功能、吸烟、NYHA分级或心衰药物,心脏恶病质均显著预测全因死亡。
临床怎么用
- 对心衰患者应评估心脏恶病质以辅助预后分层。
- 识别心脏恶病质可能有助于加强高风险患者的临床管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cardiac cachexia is a condition characterised by unintentional weight loss and muscle wasting in patients with heart failure. However, there is debate about the prognostic value of cardiac cachexia in these patients. OBJECTIVES: This meta-analysis aimed to evaluate the prognostic value of cardiac cachexia in patients who had heart failure. METHODS: We conducted a thorough literature search of the PubMed, Web of Science and Embase databases until 7 February 2025 to identify studies that examined the prognostic value of cardiac cachexia in patients with heart failure. The outcomes of interest were all-cause mortality and major adverse cardiovascular events (MACEs). The prognostic value of cachexia was determined by pooling the adjusted HR with a 95% CI. RESULTS: Nine studies, including 3821 patients with heart failure, met the inclusion criteria. Depending on the different definitions, the prevalence of cardiac cachexia varied from 11.2% to 37.8% in the included studies. A meta-analysis using a fixed-effects model showed that cardiac cachexia was associated with an increased risk of all-cause mortality (HR 1.59; 95% CI 1.34 to 1.89) and MACEs (HR 2.41; 95% CI 1.50 to 3.85). Subgroup analysis revealed that cardiac cachexia significantly predicted all-cause mortality, regardless of study design, heart failure subtypes, sample sizes, country, patients' age, definitions of cachexia, length of follow-up, baseline body mass index, left ventricular ejection fraction, and whether adjustment for renal function, smoking status, New York Heart Association class or heart failure medications was made. CONCLUSIONS: Cardiac cachexia is associated with a higher risk of all-cause mortality and MACEs in patients with heart failure. Assessing cardiac cachexia may provide valuable prognostic information for these patients.
引用
- Liu, Wu, Wang, et al. Association between cardiac cachexia and adverse outcomes in patients with heart failure: a meta-analysis of cohort studies. Heart. 2025. PMID: 40089313. doi:10.1136/heartjnl-2024-325431
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。